RE: results30 Mar 2022 05:51
Well, as usual. What a load of tosh in a fairy tale of a results report.
The only reason the so called "milestone" payment is not included in the front of the document is because its all baloney.
If there were indeed any agreement, they would have had to make it known. Instead, they include the statement to satisfy the auditors on the going concern, hence its only a 'pie in the sky' reference. As POM stated to me "the amount is just Pixie Dust", which I also agree given all the hype they made regarding market research on sales. And as POM also mentioned. "As for the deduction of US withholding tax, that is downright desperate to give it credibility to this nonsense". One only has to read what is included on page 8 where it is stated "continue negotiations with potential
commercial strategic partners for the US market" meaning nothing is agreed. Interestingly that they refer to it as a milestone payment rather than the usual upfront payment ???.
I'm pretty sure Dr Mike, who I know is in talks with the prospective US licensees, is not even aware the statement has been made.
C-19 certainly does not appear to have impacted Recordati's own end of year results as much as they allude to.
Consolidated net revenue up by 9.1%, EBITDA up by 5.8%, Operating income up by 4.5%, Net income up by 8.7%
Dividend for 2021 € 1.10 per share, of which € 0.53 already paid . JG certainly needs to be more transparent with regard to what is really going on.
Certainly No mention on supply issues, although my understanding is that Recordati may be looking at a local manufacturer.
More BS regarding the DLI which still, according to nothing being included in the ongoing concern section, will not be contributing for the next 15 months if ever. (a US$4.2 trillion (and growing) industry in 2017 [4.85trillion today]), yet no one has snapped up the app or any of its extensions and incredibly we got it at only 3.79 mill USD Mmmmm.
The only 2 positive things I got from the report are:
The Group submitted the validation study to the FDA in Q4 2021 meaning we should be receiving some sort of approval to go ahead pretty soon . I'm pretty sure any licensee wants to know when the NDA will be submitted so they can work out when it would be approved. Hence the delay in any agreement being signed, which again could happen in the next few months. And the company will certainly let the world know when that happens and not just from the contents of a fairytale results report.
And Since year end, Wanbang Biopharmaceutical has commenced the RCT, with an estimated end point of 12 months. (mind you they stated the same about the FDA phase II which ended up taking 2 years to complete and another year to submit the report).
It certainly seems this year could be the making or breaking of the company which as far as I can see is now totally dependent on getting a US license agreement made in possibly the next few months, although........
Anything could happen in